Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181943 | 0.76 | TNKS (0.47) | CCNCCDK8TNKS | |
| SCHEMBL12444827 | 0.75 | TNKS (0.34) | DRD2DRD3KCNH2CCNCCDK8 | |
| SCHEMBL14061878 | 0.75 | DGAT1 (0.65) | — | |
| SCHEMBL17543405 | 0.72 | PHGDH (0.44) | DRD2DRD3KCNH2CYP2A6PHGDH | |
| SCHEMBL4552659 | 0.72 | DRD2 (0.35) | DRD2DRD3KCNH2PHGDHDYRK1A | |
| SCHEMBL8515196 | 0.72 | HTR7 (0.41) | CYP2A6CCNCCDK8TNKS | |
| SCHEMBL1601529 | 0.71 | MAPT (0.50) | DRD2DRD3KCNH2PHGDHKDM4E | |
| SCHEMBL8349969 | 0.71 | BPTF (0.43) | CCNCCDK8TNKS | |
| SCHEMBL21723494 | 0.71 | SLC6A2 (0.48) | — | |
| SCHEMBL2326219 | 0.71 | MAPT (0.39) | DRD2DRD3KCNH2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0859775-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | claimed |
| WO-1997017346-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | claimed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6143772-A | ANTIDEPRESSANTS AND TRANQUILIZERS FORMED FROM REACTION OF BORON TRIBROMIDE AND CARBAMYL SUBSTITUTED BENZOFURAN | SYNTHELABO (FR) | 2000-11-07 | — | — | US | disclosed |
| US-6143772-A | ANTIDEPRESSANTS AND TRANQUILIZERS FORMED FROM REACTION OF BORON TRIBROMIDE AND CARBAMYL SUBSTITUTED BENZOFURAN | SYNTHELABO (FR) | 2000-11-07 | — | — | US | disclosed |
| US-6143772-A | ANTIDEPRESSANTS AND TRANQUILIZERS FORMED FROM REACTION OF BORON TRIBROMIDE AND CARBAMYL SUBSTITUTED BENZOFURAN | SYNTHELABO (FR) | 2000-11-07 | — | — | US | disclosed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | disclosed |
| EP-0859775-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| EP-0859775-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017346-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017346-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | DRD2 4398/4885DRD3 4778/4885KCNH2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.